1
|
Guo H, Wang G, Zhai Z, Huang J, Huang Z, Zhou Y, Xia X, Yao Z, Huang Y, Zhao Z, Wu C, Zhang X. Rivastigmine nasal spray for the treatment of Alzheimer's Disease: Olfactory deposition and brain delivery. Int J Pharm 2024; 652:123809. [PMID: 38224760 DOI: 10.1016/j.ijpharm.2024.123809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 12/24/2023] [Accepted: 01/12/2024] [Indexed: 01/17/2024]
Abstract
Alzheimer's disease (AD) is characterized by a gradual decline in cognitive function and memory impairment, significantly impacting the daily lives of patients. Rivastigmine (RHT), a cholinesterase inhibitor, is used to treat mild to moderate AD via oral administration. However, oral administration is associated with slow absorption rate and severe systemic side effects. RHT nasal spray (RHT-ns), as a nose-to-brain delivery system, is more promising for AD management due to its efficient brain delivery and reduced peripheral exposure. This study constructed RHT-ns for enhancing AD treatment efficacy, and meanwhile the correlation between drug olfactory deposition and drug entering into the brain was explored. A 3D-printed nasal cast was employed to quantify the drug olfactory deposition. Brain delivery of RHT-ns was quantified using fluorescence tracking and Desorption Electrospray Ionization Mass Spectrometry (DESI-MS) analysis, which showed a good correlation to the olfactory deposition. F2 (containing 1% (w/v) viscosity modifier Avicel® RC-591) with high olfactory deposition and drug brain delivery was further investigated for pharmacodynamics study. F2 exhibited superiority in AD treatment over the commercially available oral formulation. In summary, the present study showed the successful development of RHT-ns with improved olfactory deposition and enhanced brain delivery. It might provide new insight into the design and development of nose-to-brain systems for the treatment of AD.
Collapse
Affiliation(s)
- Haihua Guo
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China; Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, Guangdong, PR China
| | - Guanlin Wang
- School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, Guangdong, PR China
| | - Zizhao Zhai
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China
| | - Jiayuan Huang
- School of Medicine, Sun Yat-Sen University, Guangzhou 510006, Guangdong, PR China
| | - Zhengwei Huang
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China
| | - Yue Zhou
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China
| | - Xiao Xia
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China
| | - Zhongxuan Yao
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China
| | - Ying Huang
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China.
| | - Ziyu Zhao
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China.
| | - Chuanbin Wu
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China; Institute of Advanced Drug Delivery Systems, Jinan University, Guangzhou 510006, Guangdong, PR China
| | - Xuejuan Zhang
- College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong, PR China; Institute of Advanced Drug Delivery Systems, Jinan University, Guangzhou 510006, Guangdong, PR China.
| |
Collapse
|
2
|
Doub WH, Suman JM, Copley M, Goodey AP, Hosseini S, Mitchell JP. Laboratory Performance Testing of Aqueous Nasal Inhalation Products for Droplet/Particle Size Distribution: an Assessment from the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). AAPS PharmSciTech 2023; 24:208. [PMID: 37817001 DOI: 10.1208/s12249-023-02665-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Accepted: 09/21/2023] [Indexed: 10/12/2023] Open
Abstract
Although nasal inhalation products are becoming more and more important for the delivery of medicines, characterization of these products for quality control and assessment of bioequivalence is complicated. Most of the problems encountered are associated with the assessment of aerodynamic droplet/particle size distribution (APSD). The droplets produced by the various nasal devices are large, and for suspension products, individual droplets may contain multiple drug particles or none at all. Assessment of suspension products is further complicated by the presence of solid excipient particles. These complications make it imperative that the limitations of the instruments used for characterization as well as the underlying assumptions that govern the interpretation of data produced by these instruments are understood. In this paper, we describe various methodologies used to assess APSD for nasal inhalation products and discuss proper use, limitations, and new methodologies on the horizon.
Collapse
Affiliation(s)
- William H Doub
- OINDP In Vitro Analysis, 1430 Neffwold Ln, Kirkwood, Missouri, 63122, USA.
| | | | | | | | | | - Jolyon P Mitchell
- Jolyon Mitchell Inhaler Consulting Services Inc, 1154 St. Anthony Road, London, Ontario, N6H2R1, Canada
| |
Collapse
|
3
|
Williams G, Suman JD. In Vitro Anatomical Models for Nasal Drug Delivery. Pharmaceutics 2022; 14:pharmaceutics14071353. [PMID: 35890249 PMCID: PMC9323574 DOI: 10.3390/pharmaceutics14071353] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 05/09/2022] [Accepted: 05/25/2022] [Indexed: 12/04/2022] Open
Abstract
Nasal drug delivery has been utilized for locally acting diseases for decades. The nose is also a portal to the systemic circulation and central nervous system (CNS). In the age of SARS-CoV2, the development of nasal sprays for vaccination and prophylaxis of respiratory diseases is increasing. As the number of nasal drug delivery applications continue to grow, the role of targeted regional deposition in the nose has become a factor is nasal drug development. In vitro tools such as nasal casts help facilitate formulation and product development. Nasal deposition has been shown to be linked to pharmacokinetic outcomes. Developing an understanding of the complex nasal anatomy and intersubject variability can lead to a better understanding of where the drug will deposit. Nasal casts, which are replicas of the human nasal cavity, have evolved from models made from cadavers to complex 3D printed replicas. They can be segmented into regions of interest for quantification of deposition and different techniques have been utilized to quantify deposition. Incorporating a nasal cast program into development can help differentiate formulations or physical forms such as nasal powder versus a liquid. Nasal casts can also help develop instructions for patient use to ensure deposition in the target deposition site. However, regardless of the technique used, this in vitro tool should be validated to ensure the results reflect the in vivo situation. In silico, CFD simulation or other new developments may in future, with suitable validation, present additional approaches to current modelling, although the complexity and wide degree of variability in nasal anatomy will remain a challenge. Nonetheless, nasal anatomical models will serve as effective tools for improving the understanding of nasal drug delivery.
Collapse
Affiliation(s)
| | - Julie D. Suman
- Next Breath, an Aptar Pharma Company, Baltimore, MD 21227, USA
- Correspondence:
| |
Collapse
|
4
|
In vitro - in vivo correlation of intranasal drug deposition. Adv Drug Deliv Rev 2021; 170:340-352. [PMID: 32918968 DOI: 10.1016/j.addr.2020.09.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Revised: 09/03/2020] [Accepted: 09/07/2020] [Indexed: 12/31/2022]
Abstract
In vitro - in vivo correlation (IVIVC) allows prediction of in vivo drug deposition from a nasally inhaled drug based on in vitro drug measurements. In vitro measurements include physical particle characterization and, more recently, deposition studies using anatomical models. Currently, there is a lack of IVIVC for deposition measurements in anatomical models, especially for deposition patterns in various nasal cavity regions. Therefore, improvement of in vitro and in vivo measurement methods and knowledge about nasal deposition mechanisms should help IVIVC in the future.
Collapse
|
5
|
Nasal formulations for drug administration and characterization of nasal preparations in drug delivery. Ther Deliv 2020; 11:183-191. [PMID: 32046624 DOI: 10.4155/tde-2019-0086] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
This special report gives an insight in the rationale of utilizing the nasal cavity for drug administration and the formulation as well as characterization of nasal preparations. As the nose is an easy-to-access, noninvasive and versatile location for absorption, this route of delivery will play an increasingly important role in future drug product development both for new and repurposed drugs. The nose can be utilized for local and systemic delivery including drug delivery to the central nervous system and the immune system. Typical formulation strategies and future developments are reviewed, which nowadays mostly comprise liquid formulations. Although they are straight forward to develop, a number of aspects from choice of solvent, osmolarity, pH, viscosity and more need to be considered, which determine formulation characteristics, not at least nasal deposition. Nasal powders offer higher stability and, along with more sophisticated nasal devices, may play a major role in the future.
Collapse
|
6
|
Salade L, Wauthoz N, Goole J, Amighi K. How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. Int J Pharm 2019; 561:47-65. [PMID: 30822505 DOI: 10.1016/j.ijpharm.2019.02.026] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Revised: 02/15/2019] [Accepted: 02/15/2019] [Indexed: 12/13/2022]
Abstract
Nasal delivery offers many benefits over other conventional routes of delivery (e.g. oral or intravenous administration). Benefits include, among others, a fast onset of action, non-invasiveness and direct access to the central nervous system. The nasal cavity is not only limited to local application (e.g. rhinosinusitis) but can also provide direct access to other sites in the body (e.g. the central nervous system or systemic circulation). However, both the anatomy and the physiology of the nose impose their own limitations, such as a small volume for delivery or rapid mucociliary clearance. To meet nasal-specific criteria, the formulator has to complete a plethora of tests, in vitro and ex vivo, to assess the efficacy and tolerance of a new drug-delivery system. Moreover, depending on the desired therapeutic effect, the delivery of the drug should target a specific pathway that could potentially be achieved through a modified release of this drug. Therefore, this review focuses on specific techniques that should be performed when a nasal formulation is developed. The review covers both the tests recommended by regulatory agencies (e.g. the Food and Drug Administration) and other complementary experiments frequently performed in the field.
Collapse
Affiliation(s)
- Laurent Salade
- Laboratoire de Pharmacie Galénique et de Biopharmacie, Université libre de Bruxelles (ULB), Brussels, Belgium.
| | - Nathalie Wauthoz
- Laboratoire de Pharmacie Galénique et de Biopharmacie, Université libre de Bruxelles (ULB), Brussels, Belgium
| | - Jonathan Goole
- Laboratoire de Pharmacie Galénique et de Biopharmacie, Université libre de Bruxelles (ULB), Brussels, Belgium
| | - Karim Amighi
- Laboratoire de Pharmacie Galénique et de Biopharmacie, Université libre de Bruxelles (ULB), Brussels, Belgium
| |
Collapse
|
7
|
Roberts DL, Mitchell JP. Measurement of Aerodynamic Particle Size Distribution of Orally Inhaled Products by Cascade Impactor: How to Let the Product Specification Drive the Quality Requirements of the Cascade Impactor. AAPS PharmSciTech 2019; 20:57. [PMID: 30623259 DOI: 10.1208/s12249-018-1276-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 12/11/2018] [Indexed: 11/30/2022] Open
Abstract
The multi-stage inertial cascade impactor is used to determine the mass-weighted aerodynamic particle size distribution (APSD) as a critical quality attribute for orally inhaled products (OIPs). These apparatuses progressively size-fractionate the aerosol passing through a series of stages containing one or more nozzles, by increasing particle velocity. Nozzle sizes for a given multi-nozzle stage can be described collectively by effective diameter ([Formula: see text]), related to the cut-point size, providing the link to aerodynamic diameter. Users undertake stage mensuration periodically to assure that each stage [Formula: see text] remains within the manufacturer's tolerance, but there is no guidance on how frequently such checks should be made. We examine the philosophy that particle size-related specifications of the OIP should determine when an impactor is mensurated. Taking an example of a dry powder inhaler-generated aerosol sampled via a Next Generation Impactor with pre-separator, we find that there are only three critical stages that could have a material effect on the measured APSD specified as four groupings of stages following current regulatory practice. Furthermore, [Formula: see text] for the most critical stage having the smallest nozzle sizes could be relaxed by a factor of four or more before risking an inability to measure the mass fraction of API in the group containing the finest particles to a specification within ± 10% of nominal. We therefore conclude that users should consider letting the specification for APSD performance of an OIP in terms of accepted stage groupings drive the impactor quality requirements and frequency that stage mensuration is undertaken.
Collapse
|